Cargando…

Soluble CD30 is a new biomarker to predict two-year overall survival of adult T cell leukemia/lymphoma patients

Detalles Bibliográficos
Autores principales:	Pornkuna, Ratiorn, Takemoto, Shigeki, Hidaka, Michihiro, Haga, Yoshio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4044134/ http://dx.doi.org/10.1186/1742-4690-11-S1-P2

Ejemplares similares

Adult T-cell leukemia/lymphoma following elevation of serum levels of soluble cytokine receptors, sCD25 and sCD30
por: Takemoto, Shigeki, et al.
Publicado: (2014)

Proteins function for anti-senescence and monoclonal proliferation of ATL cells
por: Pornkuna, Ratiorn, et al.
Publicado: (2011)

Elderly ATL patients in ageing society of Japan
por: Takemoto, Shigeki, et al.
Publicado: (2011)

Differential CD30 expression in adult T-cell leukemia-lymphoma subtypes
por: Campuzano-Zuluaga, Germán, et al.
Publicado: (2014)

High soluble CD30, CD25 and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoides
por: Kadin, Marshall E., et al.
Publicado: (2011)

Clinical significance of soluble CADM1 as a novel marker for adult T-cell leukemia/lymphoma
por: Nakahata, Shingo, et al.
Publicado: (2020)

Role of CD135/CD117 on Prognosis and Overall Survival of Acute Myeloid Leukemia
por: Raeisi, Mortaza, et al.
Publicado: (2019)

CD30(+)OX40(+) Treg is associated with improved overall survival in colorectal cancer
por: Lam, Jian Hang, et al.
Publicado: (2021)

Risk factors for death and temporal trends in overall survival in patients with AIDS-associated primary central nervous system lymphoma (AIDS-PCNSL)
por: Uldrick, Thomas S, et al.
Publicado: (2012)

Brentuximab Vedotin in CD30+ Lymphomas
por: Perini, Guilherme Fleury, et al.
Publicado: (2013)

CD30 Expression and Its Functions during the Disease Progression of Adult T-Cell Leukemia/Lymphoma
por: Nakashima, Makoto, et al.
Publicado: (2023)

Adult T-cell leukemia/lymphoma with features of CD30-positive anaplastic large cell lymphoma--a case report.
por: Lee, S. N., et al.
Publicado: (1997)

CD30‐positive lymphomatous (nonleukemic) variant of adult T‐cell leukemia/lymphoma, HTLV‐1 associated
por: Podberezin, Mark, et al.
Publicado: (2020)

The oncogenic driving force of CD30 signaling‐induced chromosomal instability in adult T‐cell leukemia/lymphoma
por: Nakashima, Makoto, et al.
Publicado: (2023)

Local immunotherapy with ONCOS-102 shapes harmful tumor associated CD68+ macrophages to become beneficial cells that correlate with increased overall survival
por: Pesonen, Sari, et al.
Publicado: (2015)

GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma
por: Muranushi, Hiroyuki, et al.
Publicado: (2020)

Skin CD30(+) T cells and circulating levels of soluble CD30 are increased in patients with graft versus host disease
por: Amedei, Amedeo, et al.
Publicado: (2013)

New diagnostic marker for sepsis: soluble CD14 subtype
por: Shirakawa, K, et al.
Publicado: (2004)

Early elevation of plasma soluble CD14 subtype, a novel biomarker for sepsis, in a rabbit cecal ligation and puncture model
por: Nakamura, M, et al.
Publicado: (2008)

Immunological predictors of overall survival in treatment naïve metastatic pancreatic cancer patients
por: Farren, Matthew R, et al.
Publicado: (2015)

CD30 expression and survival in extranodal NK/T-cell lymphoma: a systematic review and meta-analysis
por: Chen, Zihang, et al.
Publicado: (2018)

Assessment of the usefulness of presepsin (soluble CD14 subtype) in septic patients
por: Nishida, T, et al.
Publicado: (2012)

Assessment of the usefulness of presepsin (soluble CD14 subtype) in septic patients
por: Nishida, T, et al.
Publicado: (2011)

Evaluation of a soluble CD14 subtype in patients with surgical sepsis
por: Fukui, Y
Publicado: (2012)

A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia/lymphoma
por: Ishitsuka, Kenji, et al.
Publicado: (2015)

Levels of Soluble CD30 and CD26 and Their Clinical Significance in Patients with Primary Immune Thrombocytopenia
por: Wang, Honghui, et al.
Publicado: (2020)

Soluble CD 163: A novel biomarker
por: Ahuja, Rajeev B.
Publicado: (2011)

Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients
por: Wang, D., et al.
Publicado: (2020)

Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas
por: Tschernia, Nicholas P, et al.
Publicado: (2023)

Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab
por: Koguchi, Yoshinobu, et al.
Publicado: (2015)

Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism
por: Labiano, Sara, et al.
Publicado: (2014)

Graft vs host disease impacts overall survival post allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia/lymphoma
por: Damlaj, Moussab, et al.
Publicado: (2018)

Single-cell motility and gene expression signature as predictors of the overall survival of act in melanoma patients
por: Martinez-Paniagua, Melisa, et al.
Publicado: (2015)

Soluble haemoglobin scavenger receptor (sCD163): a marker associated with bacteraemia
por: Gaïni, S, et al.
Publicado: (2005)

Preclinical efficacy of belinostat in combination with zidovudine in adult T-cell leukemia-lymphoma
por: Toomey, Ngoc, et al.
Publicado: (2015)

Leukemia/lymphoma development in IL-15-deficient TCR-transgenic mice
por: Dubois, Sigrid, et al.
Publicado: (2015)

Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival
por: Broucek, Joseph R, et al.
Publicado: (2013)

Malignant lymphoma of the oral cavity and the maxillofacial region: Overall survival prognostic factors
por: Guevara-Canales, Janet O., et al.
Publicado: (2013)

EZH2 expression is associated with inferior overall survival in mantle cell lymphoma
por: Martinez-Baquero, Diana, et al.
Publicado: (2021)

Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival
por: Rochefort, Pauline, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cquq1qgm318eakcoputjjkeqoj